Platform Comparison
Ambrosia vs EvaluatePharma
EvaluatePharma leads in consensus revenue forecasts and pipeline analytics. Ambrosia delivers deal-specific benchmarking with 1,600+ verified transactions, 14 calculation engines, and transparent pricing starting at $199/month.
Feature Comparison
| Feature | Ambrosia | EvaluatePharma |
|---|---|---|
| Deal Benchmarking | ||
| rNPV Analysis | ||
| Monte Carlo Simulation | ||
| Partner Matching (850+ companies) | ||
| Real-time Deal Intelligence | ||
| PDF/Excel Export | ||
| Competitive Dynamics Engine | ||
| Real Options Valuation | ||
| Consensus Revenue Forecasts | ||
| Pipeline Coverage (global) | ||
| API Access | ||
| Pricing Transparency |
Key Differentiators
Deal-Specific Benchmarking
Ambrosia benchmarks against real deal terms — upfronts, milestones, royalties, and equity stakes — not just revenue forecasts. Every data point is transaction-level.
14 Calculation Engines
rNPV, Monte Carlo, tornado sensitivity, partner matching, competitive dynamics, real options, deal waterfall, scenario comparison, and more — purpose-built for biopharma BD.
Transparent Pricing
Pro starts at $199/month (annual). No enterprise sales process, no six-figure minimums, no multi-year lock-in. EvaluatePharma starts around $50K/year.
850+ Partner Company Database
Algorithmic partner matching across 850+ pharma and biotech companies with therapeutic area affinity, deal history, and strategic fit scoring.
Pricing Comparison
Ambrosia is designed for BD professionals and biotech teams who need institutional-grade deal analytics without enterprise procurement overhead.
Ambrosia Pro
$199/month (annual)
or $299/month month-to-month
- All 14 calculation engines
- Unlimited benchmarks
- PDF/Excel export
- Partner matching
- No contract required
EvaluatePharma
~$50K+/year
Enterprise contracts only
- Sales-led procurement
- Multi-year commitments typical
- Per-seat pricing adds up
- No self-serve option
Frequently Asked Questions
How does Ambrosia compare to EvaluatePharma?
Ambrosia focuses on deal-specific benchmarking — upfront payments, milestones, royalty rates, and partner matching across 1,500+ verified transactions. EvaluatePharma excels at consensus revenue forecasts and pipeline coverage but lacks deal-specific mechanics like Monte Carlo simulation for deal terms, real options valuation, and competitive dynamics engines.
What makes Ambrosia different from EvaluatePharma?
Ambrosia provides 14 purpose-built calculation engines for biopharma deal analysis: rNPV, Monte Carlo simulation, partner matching (850+ companies), competitive dynamics, real options valuation, deal waterfall, and more. EvaluatePharma focuses on consensus forecasts and pipeline data without deal-specific benchmarking tools.
Is Ambrosia cheaper than EvaluatePharma?
Yes. Ambrosia Pro starts at $199/month (annual) or $299/month. EvaluatePharma typically requires enterprise contracts starting at approximately $50,000 per year with multi-year commitments. Ambrosia offers transparent, self-serve pricing with no sales process required.
Can Ambrosia replace EvaluatePharma for deal benchmarking?
For deal-specific benchmarking and valuation, Ambrosia provides deeper deal mechanics analysis than EvaluatePharma. If your primary need is consensus revenue forecasts and long-range pipeline analytics, EvaluatePharma may complement Ambrosia. Many BD teams use both: EvaluatePharma for market-level forecasts and Ambrosia for deal-level economics.
See the Difference With Your Own Deal
Run your deal parameters through Ambrosia's 14 engines and compare the depth of analysis to any platform on the market.